Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 82

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 82
---
 of concept (POC) as well as to inform the provisional patent application that we are currently working on.  The results      
 of this study are critical to determining the commercial viability of continued investment in this program.                        |

These product candidates
are in early stages of development and have not yet been clinically tested in the United States or elsewhere. Even if preclinical studies
show promising results, there is no guarantee that such pharmaceutical candidate will demonstrate sufficient efficacy or safety in human
populations.

The diagram below illustrates our product
pipeline across the various stages of development.

<div align='center'>49

Our leading Product Candidate --Nano-Mupirocin</div>

Nano-Mupirocin is a novel NLP-based formulation
of a potent antibiotic mupirocin. Mupirocin is an antibiotic with a unique mode of action, not shared by any other therapeutically available
antibiotic. However, due to its rapid metabolic degradation following systemic administration and extensive plasma protein binding, the
therapeutic use of this well-established agent has been limited to topical application. The novel formulation of Nano-Mupirocin is specifically
designed to overcome the challenge of rapid metabolic degradation, enabling the development of a potent systemic therapy for life-threatening
antibiotic-resistant infections.

Antibiotic resistance occurs when bacteria change
in a way that makes antibiotics less effective or ineffective against them. This makes infections harder to treat and increases the risk
of disease spread, severe illness, disability, and death. Antibiotic resistance is driven by the misuse and overuse of antibiotics in
humans, animals, and plants, and is exacerbated by poverty and inequality.

Global Research on Antimicrobial Resistance (GRAM)
Project conducted and published by Cambridge University in 2024 demonstrated that globally antibiotic-resistant infections were directly
responsible for 1.45 million deaths and contributed to 5.35 million deaths in 2022. In the US alone, antimicrobial resistance was responsible
for 47,000 deaths and contributed to 180,000 deaths in 2022. [1]. These numbers are echoed by the 2022 report published by WHO. Health
management organizations and medical professionals around the world increasingly recognize antimicrobial resistance (AMR) as one of the
most urgent and escalating threats to global health and sustainable development.

We believe that our novel liposomal Nano-Mupirocin
product candidate may potentially present significant advancement in antibiotic therapy by enabling systemic use of mupirocin, a potent
topical antibiotic previously ineffective